BioAsset

Insights / All articles

Research

Novo X Hims: From Lawsuit to Partnership — What It Means for GLP-1

By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 5 slides

Novo Nordisk and Hims & Hers have gone from courtroom opponents to business partners in about a month. Novo had been suing Hims for selling compounded, custom-made versions of semaglutide, which it called knockoff products that infringed the patents for Ozempic and Wegovy. As of March 9th, that lawsuit has been dropped and the two companies have struck a deal: Hims will offer Novo’s authorized, branded GLP-1 medicines on its platform.

The agreement moves Hims away from compounded products and toward approved, branded drugs. It also follows increased scrutiny from the FDA over the safety and necessity of compounded GLP-1 drugs.

What it means for Hims

Hims & Hers stock spiked as much as 47% in a single day after the news. That is a significant resurgence after a rocky six months in which legal battles with Novo and mounting FDA pressure had drastically weighed down the shares. Google Finance data from March 10 showed the stock near $23, up about 46% over five days but still down about 34% over the past year.

The deal provides much-needed relief, but it comes with real trade-offs. It reshapes the company’s business model significantly, moving it away from the high-margin compounded drugs that had been a major revenue driver. Hims generated $2.35 billion in revenue in 2025, and top-line growth is expected to remain strong. Branded products carry higher price tags but lower margins, though, so the shift may compress gross margins and reduce profit per prescription.

The price difference is large. Before insurance, Ozempic (intended for type 2 diabetes) costs roughly $900 to $1,200 a month and Wegovy (for weight loss) roughly $1,300 to $2,000, both from Novo Nordisk. The Hims product is listed at about $199 a month.

What it means for Novo

For Novo Nordisk, the resolution was a clear win strategically. CEO Mike Doustdar noted that the company now has more than 600,000 Wegovy pill prescriptions. Gaining Hims’ large consumer platform as a distribution channel expands Novo’s reach while shutting down a major compounding competitor. FDA commissioner Marty Makary also publicly praised the deal.

Novo is valued at $173 billion, more than 25 times Hims, and as expected it did not see the same kind of stock surge. The shares have risen slightly since the deal, up about 3% over five days to around $38.70. But with competitor Eli Lilly’s Zepbound producing better results for patients, and with the FDA recently issuing warnings to Novo, the stock is sitting around its 52-week low, down about 51% over the past year.

The GLP-1 race

The GLP-1 market is almost entirely a two-horse race between Eli Lilly and Novo Nordisk. With Wegovy on the market in 2021, Novo took a strong lead and coasted until 2025, when Eli Lilly’s Zepbound took over on superior weight loss results. Novo launched an oral Wegovy pill in late 2025, but Lilly’s faster manufacturing expansion and superior efficacy (20.2% weight loss compared to 13.7% for Wegovy) have given it a dominant position as of early 2026.

Lilly’s Zepbound now holds about 57% of the market and Novo’s Wegovy about 36%. The remaining 7% belongs to others, including AstraZeneca and Sanofi, with Roche, Pfizer, Viking Therapeutics and Amgen emerging.

With the Hims deal, we expect an increase in branded products on shelves. That would likely help both Novo and Eli Lilly, since it gets rid of a third-party competitor.

The GLP-1 market is currently valued at $101.4 billion. With experts projecting a compound annual growth rate of about 8.7%, we can expect a $180 billion valuation by 2035.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.